Literature DB >> 9685666

Norepinephrine and traumatic brain injury: a possible role in post-traumatic edema.

A A Dunn-Meynell1, M Hassanain, B E Levin.   

Abstract

Unilateral cerebral contusion is associated with an early (30 min) increase in norepinephrine (NE) turnover followed by a later (6-24 h) depression of turnover which is bilateral and widespread throughout the brain. Blockade of NE function during the first few hours after traumatic brain injury (TBI) impedes subsequent recovery of function without enlarging the size of the lesion. The current studies were carried out to characterize further the timing of the switch from increased to decreased NE turnover and to investigate the pathogenesis of the delayed recovery of function associated with blocking NE function. Adult male rats had unilateral somatosensory cortex contusions made with a 5 mm diameter impact piston. They were killed after 2 h and their brains analyzed for NE turnover by HPLC with electrochemical detection. In general, NE turnover (the ratio of 3-methoxy-4-hyroxyphenylglycol to NE levels) had returned to sham-lesion control levels in most brain regions by 2 h after either left or right sided contusions. The only exceptions were a persistent 87% increase at the lesion site after right-sided contusions and 22% and 32% increases in the contralateral cerebellum after right- and left-sided contusions, respectively. Blockade of alpha1-adrenoceptors by treatment with prazosin (3 mg/ kg, i.p.) 30 min prior to TBI produced edema in the striatum and hippocampus at 24 h which was not seen saline-treated rats nor in rats where NE reuptake was blocked with desmethylimipramine (DMI; 10 mg/kg, i.p.). DMI increased edema at the lesion site at 24 h, however. These data suggest that the early increase in NE release following unilateral cerebral contusion is protective and that this may act to stabilize the blood-brain barrier in areas adjacent to the injury site. Drugs that interfere with this enhanced noradrenergic function might enhance the damage caused by TBI. Copyright 1998 Elsevier Science B. V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9685666     DOI: 10.1016/s0006-8993(98)00524-1

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  7 in total

Review 1.  Catecholaminergic based therapies for functional recovery after TBI.

Authors:  Nicole D Osier; C Edward Dixon
Journal:  Brain Res       Date:  2015-12-19       Impact factor: 3.252

2.  Administration of haloperidol and risperidone after neurobehavioral testing hinders the recovery of traumatic brain injury-induced deficits.

Authors:  Ann N Hoffman; Jeffrey P Cheng; Ross D Zafonte; Anthony E Kline
Journal:  Life Sci       Date:  2008-08-31       Impact factor: 5.037

Review 3.  Untangling PTSD and TBI: Challenges and Strategies in Clinical Care and Research.

Authors:  Rebecca C Hendrickson; Abigail G Schindler; Kathleen F Pagulayan
Journal:  Curr Neurol Neurosci Rep       Date:  2018-11-08       Impact factor: 5.081

Review 4.  Executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology.

Authors:  Jenny E Ozga; Jessica M Povroznik; Elizabeth B Engler-Chiurazzi; Cole Vonder Haar
Journal:  Behav Pharmacol       Date:  2018-10       Impact factor: 2.293

5.  Changes of noradrenaline in brain homogenate of rats with brain injury secondary to intracerebral hemorrhage: a study of the mechanism.

Authors:  Zhi-Qiang Xu; Hua-Dong Zhou; Xiao-Jiang Jiang; Jing-Zhou Wang; Man-E Chen
Journal:  Int J Biomed Sci       Date:  2005-06

Review 6.  Catecholamines and cognition after traumatic brain injury.

Authors:  Peter O Jenkins; Mitul A Mehta; David J Sharp
Journal:  Brain       Date:  2016-06-02       Impact factor: 13.501

Review 7.  Approaches to Monitor Circuit Disruption after Traumatic Brain Injury: Frontiers in Preclinical Research.

Authors:  Gokul Krishna; Joshua A Beitchman; Caitlin E Bromberg; Theresa Currier Thomas
Journal:  Int J Mol Sci       Date:  2020-01-16       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.